Enhertu Warning and Precautions

Enhertu (Trastuzumab) is an FDA-approved medicine which is recommended for treating patients with unresectable or metastatic HER2-positive breast cancer, unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, unresectable or metastatic non-small cell lung cancer (NSCLC) and locally advanced or metastatic HER2-positive gastric/ gastroesophageal junction (GEJ) adenocarcinoma. The FDA approved this drug in 2019.  Warnings […]

Targeted Drug Therapy for Breast Cancer

Breast cancer is a disease in which cells in the breast grow unmanageable and disorderly. There are different types of breast cancer. The type/nature of breast cancer typically depends on which cells in the breast turn into cancer. Once, someone is diagnosed with this cancer, health specialists will try to figure out if it has […]